Chester A Mathis, Jr

USPTO Granted Patents = 20 (Patent Applications = 4)

EPO Patents = 3

Average Co-Inventor Count = 2.8

ph-index = 7

Forward Citations = 279(Granted Patents)

Company Filing History:

19 out of 1,863

University of Pittsburgh

patents

1 out of 15,471

University of California

patents

Years Active: 1994-2018

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10137210 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2018-11-27),

2. 9833458 - Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2017-12-05),

3. 9808541 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2017-11-07),

4. 9134328 - Methods of using benzothiazole derivative compounds and compositions (2015-09-15),

5. 8911707 - Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2014-12-16),

6. 8691185 - Benzothiazole derivative compounds, compositions and uses (2014-04-08),

7. 8580229 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2013-11-12),

8. 8404213 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2013-03-26),

9. 8343457 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2013-01-01),

10. 8236282 - Benzothiazole derivative compounds, compositions and uses (2012-08-07),

11. 8147798 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2012-04-03),

12. 8138360 - Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins (2012-03-20),

13. 7854920 - Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2010-12-21),

14. 7351401 - Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition (2008-04-01),

15. 7270800 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2007-09-18),

Title: Innovator Spotlight: Chester A Mathis, Jr. - Pioneering Alzheimer's Disease Diagnostics

Introduction: Chester A Mathis, Jr., a prolific inventor hailing from Pittsburgh, PA, has made significant strides in the field of medical diagnostics with a focus on Alzheimer's disease. With a remarkable portfolio of 20 patents, his groundbreaking work has paved the way for advanced methods of diagnosis and treatment.

Latest Patents: Chester A Mathis, Jr.'s latest patents showcase his innovative approach towards combating Alzheimer's disease. His invention of thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition represents a major breakthrough in the field. These novel derivatives have been instrumental in enhancing the accuracy of diagnosing patients with neuritic plaques, offering hope for early intervention and treatment.

Career Highlights: Chester A Mathis, Jr. has been associated with esteemed institutions such as the University of Pittsburgh, a renowned research institution in the United States. His pioneering research at the University of Pittsburgh, a leading center for medical innovation, has cemented his reputation as a trailblazer in the field of neurodegenerative diseases.

Collaborations: Throughout his career, Chester A Mathis, Jr. has collaborated with distinguished colleagues such as William E Klunk and Yanming Wang. These successful collaborations have fostered a culture of innovation and interdisciplinary research, leading to groundbreaking discoveries in the field of medical imaging and diagnostics.

Conclusion: Chester A Mathis, Jr.'s relentless dedication to advancing the field of medical diagnostics, particularly in the realm of Alzheimer's disease, underscores his commitment to improving healthcare outcomes for patients worldwide. His pioneering inventions and collaborations serve as a testament to his invaluable contributions to the field of medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com